Scripps VIVO scripps research logo

  • Index
  • Log in
  • Home
  • People
  • Organizations
  • Research
  • Events
Search form

Suppression of TH17 differentiation and autoimmunity by a synthetic ROR ligand

Academic Article
uri icon
  • Overview
  • Identity
  • Additional Document Info
  • View All
scroll to property group menus

Overview

authors

  • Solt, Laura A.
  • Kumar, N.
  • Nuhant, P.
  • Wang, Y. J.
  • Lauer, J. L.
  • Liu, J.
  • Istrate, M. A.
  • Kamenecka, Theodore
  • Roush, William
  • Vidovic, D.
  • Schurer, S. C.
  • Xu, J. H.
  • Wagoner, G.
  • Drew, P. D.
  • Griffin, Patrick
  • Burris, Thomas

publication date

  • April 2011

journal

  • Nature  Journal

abstract

  • T-helper cells that produce interleukin-17 (T(H)17 cells) are a recently identified CD4(+) T-cell subset with characterized pathological roles in autoimmune diseases. The nuclear receptors retinoic-acid-receptor-related orphan receptors α and γt (RORα and RORγt, respectively) have indispensible roles in the development of this cell type. Here we present SR1001, a high-affinity synthetic ligand-the first in a new class of compound-that is specific to both RORα and RORγt and which inhibits T(H)17 cell differentiation and function. SR1001 binds specifically to the ligand-binding domains of RORα and RORγt, inducing a conformational change within the ligand-binding domain that encompasses the repositioning of helix 12 and leads to diminished affinity for co-activators and increased affinity for co-repressors, resulting in suppression of the receptors' transcriptional activity. SR1001 inhibited the development of murine T(H)17 cells, as demonstrated by inhibition of interleukin-17A gene expression and protein production. Furthermore, SR1001 inhibited the expression of cytokines when added to differentiated murine or human T(H)17 cells. Finally, SR1001 effectively suppressed the clinical severity of autoimmune disease in mice. Our data demonstrate the feasibility of targeting the orphan receptors RORα and RORγt to inhibit specifically T(H)17 cell differentiation and function, and indicate that this novel class of compound has potential utility in the treatment of autoimmune diseases.

subject areas

  • Animals
  • Autoimmunity
  • Cell Differentiation
  • Drug Inverse Agonism
  • HEK293 Cells
  • Humans
  • Interleukin-17
  • Interleukins
  • Ligands
  • Mice
  • Mice, Inbred C57BL
  • Models, Molecular
  • Nuclear Receptor Subfamily 1, Group F, Member 1
  • Nuclear Receptor Subfamily 1, Group F, Member 3
  • Sulfonamides
  • Th17 Cells
  • Thiazoles
scroll to property group menus

Identity

PubMed Central ID

  • PMC3148894

International Standard Serial Number (ISSN)

  • 0028-0836

Digital Object Identifier (DOI)

  • 10.1038/nature10075

PubMed ID

  • 21499262
scroll to property group menus

Additional Document Info

start page

  • 491

end page

  • 494

volume

  • 472

issue

  • 7344

©2021 The Scripps Research Institute | Terms of Use | Powered by VIVO

  • About
  • Contact Us
  • Support